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ABSTRACT 
Background: Field-testing is a quality assurance criterion in the development of patient decision-
support technologies (PDSTs), as identified in the consensus statement of the International Patient 
Decision Aids Standards Collaboration. We incorporated field-testing into the development of a 
Web-based, prostate-specific antigen PDST called Prosdex, which was commissioned as part of the 
UK Prostate Cancer Risk Management Programme. 
Objectives: The aim of this study was to develop a model for the future field-testing of PDSTs, 
based on the field-testing of Prosdex. Our objectives were (1) to explore the reactions of men to 
evolving prototypes of Prosdex, (2) to assess the effect of these responses on the development 
process, and (3) to develop a model for field-testing PDSTs based on the responses and their effect 
on the development process. 
Methods: Semistructured interviews were conducted with the men after they had viewed evolving 
prototypes of Prosdex in their homes. The men were grouped according to the prototype viewed. 
Men between 40 and 75 years of age were recruited from two family practices in different parts of 
Wales, United Kingdom. In the interviews, the men were asked for their views on Prosdex, both as 
a whole and in relation to specific sections such as the introduction and video clips. Comments and 
technical issues that arose during the viewings were noted and fed back to the developers in order 
to produce subsequent prototypes. 
Results: A total of 27 men were interviewed, in five groups, according to the five prototypes of 
Prosdex that were developed. The two main themes from the interviews were the responses to the 
information provided in Prosdex and the responses to specific features of Prosdex. Within these 
themes, two of the most frequently encountered categories were detail of the information provided 
and balance between contrasting viewpoints. Criticisms were encountered, particularly with respect 
to navigation of the site. In addition, we found that participants made little use of the decision-
making scale. The introduction of an interactive contents page to prototype 2 was the main change 
made to Prosdex as a result of the field-testing. Based on our findings, a model for the field-testing 
of PDSTs was developed, involving an exploratory field-testing stage between the planning stage 
and the development of the first prototype, and followed by the prototype field-testing stage, 
leading to the final PDST. 
Conclusions: In the field-testing of Prosdex, a Web-based prostate-specific antigen PDST, the 
responses of interviewed men were generally favorable. As a consequence of the responses, an 
interactive contents page was added to the site. We developed a model for the future field-testing 
of PDSTs, involving two stages: exploratory field-testing and prototype field-testing. 
(J Med Internet Res 2007;9(3):e21) 
doi:10.2196/jmir.9.3.e21 
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Introduction 
Field-testing is increasingly recognized as an important step in the quality assurance of patient 
decision-support technologies (PDSTs), interventions commonly known as decision aids. This was 
underlined by the International Patient Decision Aids Standards (IPDAS) Collaboration consensus 
statement on PDST quality, the product of a Delphi process involving all major stakeholder groups, 
at the end of which nine domains of PDST quality criteria were agreed upon [1]. One of these 
domains was systematic developmental process, which incorporated the criterion of field-testing in 
order to show that a decision aid was acceptable to patients [1]. IPDAS, however, did not define 
field-testing, and, more broadly, the PDST/decision aid literature gives very little guidance in this 
respect [2]. Furthermore, there are potentially two processes encapsulated in field-testing: (1) the 
development of a prototype with users, and (2) the “live” testing of a refined prototype. 
In 2002, we were commissioned to develop a Web-based, prostate-specific antigen (PSA) PDST, 
called Prosdex, and included field-testing as part of the development process [3]. Prosdex formed 
part of the UK Prostate Cancer Risk Management Programme strategy, led by the National Cancer 
Screening Programmes, which had, at its heart, the concept of informed choice in PSA testing [4]. 
According to the strategy, UK men interested in the PSA test would be provided with information to 
enable them, with their family doctor, to make an informed decision. Prosdex was developed in 
order to present this information in the format of a Web-based, multimedia, interactive PDST. This 
opportunity for users to explore the information presented on PSA explains the full name of 
Prosdex: Prostate-Specific Antigen Decision Explorer [3]. 
Prosdex presents evidence-based information about prostate cancer and PSA testing, encouraging 
users to weigh the pros and cons of testing for themselves. Much of the information came from an 
earlier, paper-based decision aid for PSA testing commissioned as part of the UK Prostate Cancer 
Risk Management Programme and approved by its Scientific Reference Group [4]. Of particular 
importance in that decision aid were the statistical/epidemiological data, which allowed us to 
present some of the more controversial issues, such as the validity of the PSA test. For instance, 
we stated in Prosdex that two thirds of men with a raised PSA test do not have prostate cancer. 
The development of Prosdex was also underpinned by a systematic review of PSA decision aids, 
undertaken not only to garner information on extant PDSTs, but also to explore their effects. We 
found that the evaluations of PSA decision aids demonstrated, fairly consistently, an improvement 
in knowledge about PSA testing and prostate cancer; in contrast, however, no clear effect was 
found on PSA testing itself [5]. The findings were broadly similar to those of a Cochrane review of 
the effect of PDSTs that considered a range of clinical domains [6]. This review found that patients 
who use PDSTs participate more, know more, have more realistic expectations of benefits and 
harms, and are more likely to receive an option with outcomes they most value [6,7]. 
Narrative is also employed in Prosdex to present information. Specifically, there are 25 video clips 
of enacted patient experiences about the PSA test and subsequent investigations/treatments. The 
transcripts for these clips were obtained from a qualitative study of men’s experiences of PSA 
testing [8]. Informed choice is actively encouraged in Prosdex through structured decision support 
in the form of a decision-making scale. The link to this functionality lies on the top right of each 
page, thereby allowing users to weigh the impact of the information in that particular page on their 
decision-making process. Specifically, they are able to indicate whether they are for, against, or 
undecided about PSA testing on the basis of that information. Each decision is then added, or 
“stacked,” in the decision summary to produce a cumulative result for the pages viewed. Prosdex 
has been designed to cater to the needs of users with visual and hearing difficulties. Consequently, 
there is a voice-over option to which the website defaults, but which can be switched off; there are 
also subtitles for the video clips. 
 
 
Figure 1a. Prosdex screenshots 
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Figure 1b. Prosdex screenshots 
 
In this study, we attempted to capture the process of field-testing Prosdex by interviewing men 
who used it. Furthermore, by introducing evolving versions of Prosdex, we hoped that the series of 
interviews would help us, as developers, to identify strengths and weaknesses and modify the 
prototype. Beyond this, however, we wanted to explore the role of field-testing in the development 
of PDSTs. Specifically, our aim in this study was to develop a model for future field-testing of 
PDSTs. Our objectives were: (1) to explore the responses of men to evolving prototypes of 
Prosdex, (2) to assess the effect of these responses on the development process, and (3) to 
develop a model for field-testing PDSTs based on the responses and their effect on the 
development process. 
 
Methods 
A qualitative study design was employed using semistructured interviews and incremental 
prototypes of Prosdex. Men between the ages of 40 and 75 were recruited, the target age range for 
the UK Prostate Cancer Risk Management Programme. The men were recruited from two family 
doctor practices in Wales, United Kingdom: one in a coastal/rural town and the other in a 
postindustrial town. The men had previously participated in a randomized controlled trial examining 
the effect of a brief patient decision aid—a written one-page leaflet given to the intervention group. 
All of the men in that trial completed a written questionnaire exploring their knowledge of and 
attitudes toward PSA testing and their intention to be tested [9]. At the end of the questionnaire, 
the men were asked to indicate whether they would be interested in participating in the qualitative 
study, and those who did so were sent invitation letters, information sheets, and consent forms by 
the research team. 
Men who agreed to participate were contacted, and arrangements were made for them to view a 
stand-alone prototype of Prosdex on a laptop, in their homes, in the presence of one of the 
researchers (RE), who sat behind them. The researcher did not impart any advice or answer 
questions on content matters during the viewing—questions were, however, addressed during the 
subsequent interview. Technical questions, particularly those relating to difficulties in using Prosdex 
(eg, navigational problems), were answered contemporaneously. In the event of the men being 
unable to use a computer mouse, the researcher performed this function for them, opening 
specified Web pages but not giving any direction on use. The men were asked to indicate when 
they had finished using Prosdex and were then given a 5- to 10-minute break before the interview. 
In the interview, the men were initially asked for their opinion of Prosdex in general. Then, they 
were asked for their views on specific aspects of Prosdex, some of which are listed in Table 1. 
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Table 1. Specific aspects of Prosdex discussed in the interview 
 
The transcribed interviews were coded independently by RE and GE with qualitative software, 
Atlas-ti (version 4.1), and using the technique of constant comparison [10,11]. The coded 
transcripts were then subjected to thematic analysis by RE and GE. Technical issues that arose 
during the viewings were noted by RE, and those, in addition to comments from the interviews, 
were fed back to the multimedia designer. Feedback occurred after a group of men had viewed 
each prototype, in order to maintain version control. This iterative development process resulted in 
evolving prototypes of Prosdex. The content of the site, however, stayed the same throughout. 
Finally, after analyzing the men’s responses and subsequent changes to Prosdex, we developed a 
model for field-testing PDSTs. 
 
Results 
The results are presented in five sections: (1) characteristics of the interviewed men, (2) data from 
themes, (3) analysis of data, (4) outline of changes made to Prosdex, (5) a model for field-testing 
PDSTs. 
Characteristics of the Interviewed Men 
A total of 27 men were interviewed after using Prosdex, between September 2004 and February 
2005, and they were grouped according to the prototype viewed. There were five groups; the 
group that used prototype 1 (7 men) was deliberately larger than the others in order to capture the 
majority of the technical problems before the production of further prototypes. The men viewed 
Prosdex for between 15 and 45 minutes. 
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Table 2. Characteristics of the interviewed men 
 
Data From the Themes 
Two main themes were identified, and they are shown in Table 3 and Table 4, along with their 
categories and illustrative quotations. The respondent/man is identified according to the prototype 
group; for instance, the third man to use and be interviewed about prototype 4 is P4,i3. It should 
be noted, however, that the quotations are presented in relation to the themes for the whole 
sample, not in relation to the developing prototypes. 
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Table 3. Theme 1: Responses to the Information Provided in 
Prosdex - Categories and quotations 
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Table 4. Theme 2: Responses to Specific Features of Prosdex 
- Categories and Quotations 
 
Analysis of Data 
Theme 1: Responses to the Information Provided in Prosdex 
Three main categories were identified: (1) detail, (2) balance, (3) suggestions to improve the 
information. 
Detail 
In general, the men were happy with the amount of information provided (P1,i4), although there 
was an appreciation of the difficulty in deciding on the level of detail (P1,i2) and a realization of the 
weakness of the evidence base (P4,i2). Openness on sensitive issues was commended (P1,i7), and 
there was some evidence that the site helped to clarify some of the complexities and uncertainties 
of PSA testing (P1,i3). This level of detail was noted, in some cases, to be helpful for the decision-
making process (P5,i1). 
Balance 
Mostly positive comments were made about the balance of the information on the site. The 
presentation of uncertainty was commended (P1,i6), and there was an appreciation of the 
difficulties involved in presenting such information (P3,i4). Nonetheless, there were some 
dissenting comments in this respect; for instance, one man would have preferred a greater 
emphasis on the benign nature of most prostate conditions (P4,i1). 
Suggestions to Improve the Information 
Specific suggestions were made to improve on the information on the site. These included a desire 
for more background anatomical information (P1,i3), more diagrams (P1,i5), more age-specific 
information (P2,i6), and a preference for a bibliography (P5,i3). In addition, there were comments 
on the lack of information about other European countries (P1,i2), and some criticism of the 
presentation of the statistical information. 
Theme 2: Responses to Specific Features of Prosdex 
The four specific features that were discussed in greatest detail were (1) navigation of the site, (2) 
video clips, (3) voice-over, (4) decision-making scale. 
Navigation of the Site 
The navigation difficulties with prototype 1 resulted in the most significant criticism of Prosdex 
(P1,i6). Men using later prototypes were less critical of the navigation, almost certainly due to the 
interactive contents page developed after field-testing of prototype 1 (P2,i2). 
Video Clips 
The two main categories identified here were those of balance and detail. In terms of balance, the 
responses were positive (eg, regarding our presentation of contrasting opinions and experiences) 
(P1,i2). There was also an appreciation of the difficulty in striking such a balance, particularly when 
dealing with sensitive issues (P1,i5). 
With respect to detail, there were two specific criticisms. One man expressed a desire for more 
graphic detail in relation to the descriptions of prostate investigations and treatments (P5,i2). 
Another man expressed a preference for less choice of video clips for a particular issue, and for 
greater detail in those clips (P2,i6). 
Voice-Over 
The category of note here was clarity, and, in this respect, the responses were mixed. 
Only one man (P2,i4) decided to switch off the voice-over using the button provided. Of those who 
left the voice-over on, some gave positive responses (P1,i7); in particular, one man found the 
process of reading to be made easier (P3,i3) with the voice-over. In terms of negative responses, 
one man found the voice confusing (P2,i1), and another found the voice-over to restrict his use of 
Prosdex(P2,i5). 
Decision-Making Scale 
The significant category here was limited utility, a consequence of the men making little use of the 
decision-making scale (P1,i6; P2,i3; P4,i2). The reasons given for the minimal use of the scale 
varied. For one man it related to the positioning of the scale on the screen (P1,i6); for another, it 
seemed to be caused by a limited understanding of when to use the scale (P2,i2). As the viewing of 
Prosdex progressed, one man focused on the content and stopped using the scale (P1,i5). One 
solution offered for this was audiovisual prompts/reminders to use the scale (P2,i1). 
Outline of Changes Made to Prosdex During the Field-Testing 
Navigation 
The major change made to Prosdex during the course of field-testing was to improve the 
navigation of the site. As previously noted, men using prototype 1 found it difficult to keep a record 
of which pages they had viewed (P1,i6). Consequently, for prototype 2, an interactive contents 
page was developed that not only indicated to the men which pages they had visited, but also 
allowed them to navigate directly to sections of interest. This change improved the navigation 
significantly for the men, and no other amendments were deemed necessary in this respect. 
Content 
The content, both text and video, remained unchanged in Prosdex since the responses regarding 
this were generally positive, in particular about the detail and balance of the information on the 
site. As highlighted above, there were some specific suggestions, and these were considered by the 
developers. It was decided, however, that either the information was, in fact, already present in 
the site, or that the requested content would have overwhelmed sections that were already very 
detailed. An example of this was the request for a pan-European comparison of PSA screening 
(P1,i2). Our decision to keep the comparison at a UK/USA level was made in order to provide the 
UK target audience with a relevant comparison of different practices. 
Voice-Over 
Despite the mixed responses to the voice-over functionality, it was retained in Prosdex. As 
previously noted, only one of the respondents (P2,i4) asked for the voice-over to be switched off, 
and only two of the respondents (P2,i1 and P2,i5) stated that the voice-over affected their reading 
of the text. Furthermore, as developers of a publicly available health information site, we were 
obliged to make arrangements for visually-impaired users or those with reading difficulties. Finally, 
we were confident that the criticisms raised could be addressed by the clearly marked option on 
the site to switch off the voice-over. 
Decision-Making Scale 
The decision-making scale was also retained in Prosdex despite its low usage in the field-testing. 
Our reason for doing so was based on the original design for Prosdex, one of the key features of 
which was a tool for interactive decision making. There was also no evidence that the scale 
interfered with other components of the site, and it was agreed that some users might find it to be 
of benefit. 
A Model for Field-Testing PDSTs 
For the purposes of developing a model for field-testing PDSTs, we reflected on the qualitative data 
from the men’s responses and on the changes made to Prosdex. We found that PDST field-testing 
was composed of two distinct processes: (1) a process of user involvement in the development of 
the PDST, and (2) user trials of one or more prototypes. Consequently, for the model, we divided 
field-testing into two stages (Figure 2). In the first stage, which we defined as exploratory field-
testing, users would be asked to look at specific components of the PDST early in its development, 
before the construction of the first prototype, thus allowing users to influence key decisions early 
on. In the second stage, which we defined as prototype field-testing, users would be shown 
successive prototypes, as in this study, but with reference to changes made during the 
development process. 
 
 
Figure 2. Proposed model for field-testing PDSTs 
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figure] 
 
 
Discussion 
Summary of Main Findings 
The two main themes from the interviews were the responses to the information provided in 
Prosdex and the responses to specific features of Prosdex. Within these themes, two of the most 
frequently encountered categories were detail of the information provided and balance between 
contrasting viewpoints. Criticisms were, however, encountered, particularly with respect to the 
navigation of the site. In addition, we found that the men made little use of the decision-making 
scale. 
The introduction of an interactive contents page to prototype 2 was the main change made to 
Prosdex as a result of the field-testing. Other aspects of the site, notably the content, voice-over, 
and decision-making scale, were not changed, for two reasons. First, the collective responses did 
not justify radical amendments such as removing specific features. Second, there were factors 
other than the men’s responses to consider in the development process, notably PDST quality 
criteria. For example, one of the reasons for retaining the decision-making scale was that values 
clarification is an internationally recognized quality criterion for PDSTs [1]. 
Finally, based on our findings, a model for the field-testing of PDSTs was developed, comprising 
two stages: exploratory field-testing and prototype field-testing. 
Limitations of the Study 
Only two family practices were used to recruit men for this study. It would have been desirable to 
recruit men from a greater number of practices to ensure a broader socioeconomic and geographic 
population distribution. Another limitation was the fact that the men had previously participated in 
a randomized controlled trial of a brief PSA paper decision aid in which they all had completed a 
written questionnaire. However, we would argue that this study differed significantly in that it 
focused on the details and technical aspects of a specific PDST, Prosdex, which was not featured in 
the trial. A qualitative methodology, semistructured interviews, was employed in this study. 
Arguably, however, the study design was descriptive, using qualitative techniques and employing a 
relatively technical, specific interview schedule, which, to an extent, is in accordance with the 
model stage of the complex intervention framework, as developed by Campbell et al [12]. 
The validity of the study’s findings is potentially open to criticism as no formal measures were 
employed in this respect. For instance, there was no triangulation, using data from other methods 
such as surveys [11]. Such an approach would, however, have been impractical in our opinion due 
to the dependency in this study on the presence of a researcher to facilitate the viewing of the 
PDST. Moreover, we would contend that the observational data from these viewings provided a 
degree of corroboration. For instance, the comments from group 1 on the navigational difficulties 
accorded with the researcher’s observations. Finally, respondent validation was not used as the 
men’s responses were dependent on their immediate recollections and views of Prosdex [11]. 
Corroborating these responses with the results at a later date would not, in our opinion, have been 
a reliable method. 
Comparisons With Previous Work 
As noted earlier, we previously undertook a systematic review of evaluations of PDSTs on the topic 
of PSA [5]. In contrast, there are, to date, no studies that specifically consider the field-testing of 
PSA PDSTs. There are, however, such studies in other clinical areas, although most of these focus 
on the usability and acceptability of prototype PDSTs, corresponding to the prototype field-testing 
stage of our proposed model. For example, Irwin et al found in a pilot study that a decision aid for 
women with breast cancer was described as helpful by most of the users [13]. Feldman-Stewart 
and colleagues field-tested a PDST designed for men with early stage prostate cancer with a group 
of “surrogate patients”—men, without prostate cancer, of the same age as the target group of the 
PDST [14]. It was observed that the men were able to understand the information provided and 
that most were able to express treatment choices. In a noncancer setting, Lalonde et al found high 
levels of acceptability for a PDST aimed at improving the knowledge of patients with 
hypertension/hyperlipidemia [15]. Finally, and significantly, in the context of a multimedia Web-
based PDST such as Prosdex, Diefenbach and Butz field-tested a multimedia interactive education 
system for prostate cancer patients and found high levels of acceptability [16]. 
The importance of prototype field-testing was highlighted by O’Donnell and colleagues in a review 
of the implementation of patient decision aids in clinical practice [7]. One of the significant barriers 
for implementation was described as “usability for diverse patients.” Specifically, the authors noted 
the lack of evidence on the assessment of the readability of PDSTs—a weakness shared by 
Prosdex—though they welcomed the finding, in the Cochrane review inventory, that most PDSTs 
were developed for general audiences (eg, grade 8 reading level) [6]. O’Donnell et al suggested 
further research on how PDSTs could improve the decision quality for people who vary by 
demographic characteristics. This is an important statement as it extends the potential scope of 
prototype field-testing. Moreover, there is a strong argument that our proposed second stage of 
field-testing only becomes valid if it has taken into consideration the diversity of the target 
audience. 
There is an even greater research deficit for the exploratory field-testing of PDSTs. In one of the 
few studies available, Sawka et al described the development of a decision aid for choice of surgical 
treatment for breast cancer [17]. Notably, the study involved a needs assessment stage during 
which focus groups were held involving women with a previous diagnosis of breast cancer, and 
which considered issues such as information the women wished they had received at diagnosis. 
Subsequently, the decision aid was developed in conjunction with a steering group that revised 
various drafts of the aid. Finally, in a pilot study, almost all of the women responded positively to 
the decision aid. This twin approach of needs assessment and pilot study forms a strong basis for 
the development of a decision aid and, moreover, corresponds, in our opinion, to our proposed 
two-stage model for field-testing PDSTs. 
The paucity of research into field-testing has implications for developers of PDST quality criteria. As 
previously mentioned, field-testing is, at present, regarded as an important criterion in the IPDAS 
framework. Moreover, this framework gives direction for the development process of PDSTs. 
Arguably, components of that development process are very similar to the two stages of field-
testing that we propose. This is particularly true of the exploratory stage, and it again raises the 
question of the definition of field-testing. What is certain, however, is that with such little 
understanding of this criterion, it is difficult to contend, at present, that firm assessments can be 
made against it [1]. 
Implications for Clinical Practice and Future Research 
Our proposed two-stage model and, in particular, the exploratory field-testing stage, raises a 
number of challenges for developers of PDSTs, not least of which is the difficulty of accommodating 
it within the pressures of deadlines and budgets. There is also the challenge of balancing the 
opinions of users with those of experts/scientific reference groups, particularly in situations of 
clinical uncertainty/equipoise. Arguably, the model is too simplistic in that it presupposes a linear 
progression from exploratory to prototype field-testing. In reality, more complex PDSTs might 
follow a different development path wherein the factual content, for instance, would require both 
exploratory and prototype field-testing in order to develop other features of the PDST, for example, 
videos of patient experiences. Moreover, the model does not take into account contextual factors, 
such as the influence of family/friends and health professionals, which could have an impact on the 
utilization of PDSTs in a natural setting. Nevertheless, the principle of two-stage field-testing for 
PDSTs, whether applied in parts or as a whole, still holds true in our opinion; we suggest further 
research to test it and other future models of field-testing. In doing so, it is hoped that reviewers of 
PDSTs, and international standard groups such as IPDAS, will have at their disposal a clearer 
definition of field-testing. 
Conclusions 
In the field-testing of Prosdex, a Web-based PSA PDST, the responses of interviewed men were 
generally favorable. As a consequence of the responses, an interactive contents page was added to 
the site. We developed a model for the future field-testing of PDSTs involving two stages: 
exploratory field-testing and prototype field-testing. 
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